Recombinant CD19 (Tafasitamab Biosimilar) antibody
This Mammalian Cells Monoclonal antibody specifically detects CD19 (Tafasitamab Biosimilar) in ELISA. It exhibits reactivity toward Human.
Catalog No. ABIN7488054
$336.06
Plus shipping costs $50.00
Shipping to:
United States
Delivery in 7 to 8 Business Days
Quick Overview for Recombinant CD19 (Tafasitamab Biosimilar) antibody (ABIN7488054)
Target
CD19 (Tafasitamab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Mammalian Cells
Clonality
Monoclonal
Conjugate
This CD19 (Tafasitamab Biosimilar) antibody is un-conjugated
Application
ELISA
Grade
Research Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Tafasitamab Biosimilar - Anti-CD19 mAb
-
Characteristics
- Antibody Type: IgG1-G2-kappa
-
Purification
- Recombinant antibody expressed in mammalien cells and purified.
-
Isotype
- IgG1
-
-
-
-
Restrictions
- For Research Use only
-
-
-
Buffer
- PBS pH 7.5
-
Storage
- -80 °C
-
Storage Comment
- store at -80°C
-
-
- CD19 (Tafasitamab Biosimilar)
-
Target Type
- Biosimilar
-
Background
-
MOR-00208,MOR-208,XENP-5574,XMP-5574,XmAb-5574,Xmab-CD19
Tafasitamab is a humanized monoclonal antibody that targets CD19. It is used for the treatment of B-cell malignancies. The CD19 surface protein is highly expressed on the surface of B-cells where it enhances B-cell receptor signaling. CD19 is especially expressed in cases of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL). By its activity, tafasatimab induces the lysis of B-cells. -
CAS-No
- 1422527-84-1
Target
-
You are here:
